Frost & Sullivan Independent Equity Research
Cellect Biotechnology Ltd.: Significant recently reported findings open the ApoGraft™ platform to also be used in the fat-derived stem cell segment; price target raised to $16.9
![logo_cellect-biotech logo_cellect-biotech](https://www.frostequityresearch.com/wp-content/uploads/elementor/thumbs/logo_cellect-biotech-nx7oenqvj2y33m2uhxiuo5wv2s7xme8mc1ykanhgzk.jpg)
Company: Cellect Biotechnology Ltd.
Sector: Biotechnology
Report type: Quarterly Update, Q3
Published on: December 19, 2017